Indeed, I wonder if we get more cohort 3 data or even early cohort 4 before ASCO on 2nd June?
Last link from me for a bit, but Novartis's Pluvicto data is worth looking at https://www.pluvicto-hcp.com/psma-positive-mcrpc/efficacy
30% ORR with 6% complete responses from 319 patients in their P3 trial. For Clarity to get a complete response already is pretty stunning.
You'd have to think at the very least the likes of Lantheus are on the prowl here, particularly given the Point data.
Anyway, will wait the next data release and see where things sit then - but after 4 multi billion dollar buyouts in 6 months I've no idea how anyone could view Clarity as expensive at a $750m valuation
Research/Valuation, page-370
-
- There are more pages in this discussion • 227 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CU6 (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$6.03 |
Change
-0.270(4.29%) |
Mkt cap ! $1.899B | |||
| Open | High | Low | Value | Volume |
| $6.30 | $6.45 | $5.65 | $13.43M | 2.223M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 14784 | $5.96 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $6.04 | 4000 | 2 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| CU6 (ASX) Chart |